An activatable, carrier-free, triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer highly permeable targeted chemotherapy

Abstract

Highly permeable targeted chemotherapy is highly desired for treating non-small cell lung cancer (NSCLC). In this study, a novel stimulus-responsive, carrier-free, and triple-combination nano-system (identified as UA@CA4-SS-Cer nanoparticles [NPs]) is developed for the systemic treatment of ALK/EGFR dual-mutant NSCLC. This nanomedicine addresses concerns related to low drug loading and inefficient drug permeability and it provides the foundation for developing GSH-sensitive nanoparticles for improved drug delivery.